Key Highlights
- Nexalin Technology is appealing a Nasdaq delisting determination after failing to regain minimum bid price compliance, with shareholders granting the board authority for a reverse split of up to 1-for-100 just days before the quarterly filing.
- A Brazilian clinical trial showed a 77.8% anxiety response rate using the company's non-invasive brain stimulation device, its strongest published efficacy signal to date, though from a small single-center open-label study without a sham control.
- Cash stood at just over $1 million with a going-concern warning, while quarterly Revenue fell to $12,161 from $70,588 a year earlier, reflecting a Business still years from meaningful commercial scale.
Nexalin Technology, Inc. (NASDAQ:NXL) has produced the clinical headlines a small neurotechnology developer wants in 2026: a 77.8% anxiety response rate from a Brazilian trial, a new U.S. patent, and an FDA pivotal study now recruiting. Its shareholders have watched the stock slide to about $0.35 and a Market Value near $7.6 million.
The two narratives collided over three weeks. On 24 July, Nasdaq told the Houston company it would be delisted. On 11 August, shareholders gave the board authority for a Reverse Stock Split of up to 1-for-100. On 12 August, the second-quarter report showed just over $1 million of cash and a going-concern warning.
Nexalin builds non-invasive brain-stimulation devices - headsets that pass a low-level alternating current through the skull to reach deeper brain structures without surgery or implants. It calls the approach Deep Intracranial Frequency Stimulation, or DIFS.
What Happened
Nasdaq first flagged Nexalin on 21 January 2026, after the stock closed below $1.00 for 30 consecutive business days, breaching Listing Rule 5550(a)(2). It had until 20 July to comply. It did not. On 24 July, Nasdaq issued a delisting determination and ruled Nexalin ineligible for a second grace period because stockholders' Equity sat below the $5 million level that extension requires. Trading was set to be suspended on 4 August.
Nexalin appealed before the 31 July deadline. A timely hearing request stays both the suspension and the filing of Form 25-NSE - the notice that formally strips a security from the exchange - until a Nasdaq Hearings Panel rules. The company must present a compliance plan, and acknowledged it could include a reverse split.
Hence the 11 August annual meeting. Holders of 13.9 million shares, about 63% of the register, approved a reverse split at a ratio between 1-for-2 and 1-for-100, with the board choosing the number. A 2026 equity incentive plan passed. Two proposals failed: authorising 10 million preferred shares, and adding officer exculpation to the charter.
Why It Matters
A reverse split is the standard mechanical fix for a sub-$1 share price, and Nexalin now has the tool. It is not a cure: panels want evidence a company can hold a standard once regained, and the equity shortfall Nasdaq cited is a separate problem from the share price.
The rejected preferred-stock proposal matters more than the tally suggests. Authorised Preferred Shares are a common instrument for micro-caps needing structured Capital quickly. Without them, near-term funding narrows largely to common stock, principally the at-the-market facility, priced against a share close to its 52-week low of $0.31.
The Numbers
The June clinical release remains Nexalin's strongest published efficacy signal. In an eight-week, single-centre, open-label study at the University of Sao Paulo's Institute of Psychiatry, patients received 20 sessions of a 15 milliamp, 77.5 Hz DIFS protocol over four weeks. The anxiety response rate was 77.8% at the end of treatment, with Hamilton Anxiety Rating Scale scores - where a larger fall means less anxiety - down 18.30 points by session 20 and holding at follow-up. Depression scores fell 9.90 points, with 66.7% response and remission rates.
The commercial picture is thinner. Second-quarter revenue was $12,161, down from $70,588 a year earlier. First-half revenue was $27,111 against $111,603, all of it domestic in 2026; the 2025 comparative included $80,048 of international sales.
The net loss widened to $2.24 million in the quarter from $1.58 million, and to $4.34 million for the half from $3.57 million, or $0.21 per share. First-half operating costs of $4.39 million comprised $1.58 million of selling and administrative expense, $1.00 million of salaries, $0.91 million of Research and Development and $0.90 million of professional fees.
Cash was $1.00 million on 30 June, up from $0.65 million at year-end, but operations consumed $3.51 million over the half. Stockholders' equity was $1.52 million on total Assets of $3.00 million, with an accumulated Deficit of $97.2 million and 22.0 million shares outstanding. The at-the-market programme bridged the gap, raising roughly $895,000 net from 1,858,344 shares and leaving about $2.65 million of capacity.
What It Means for the Company
Nexalin's strategy rests on moving from a legacy first-generation device to its Gen-2 and Gen-3 platforms. The 15 milliamp Gen-2 device is approved in China, Brazil, Oman and Israel, though none of those markets produced meaningful revenue in the first half. The FDA accepted a Q-Submission covering Alzheimer's disease and dementia in October 2025, with design work since informed by real-world data from Beijing's Xuanwu Hospital.
The nearer-term U.S. catalyst is HALO Clarity, a Gen-3 headset for moderate-to-severe insomnia. Nexalin engaged contract research group Lindus Health in April under a scope of work worth about $945,000, of which $374,000 had been incurred by 30 June. The trial is randomised, triple-blinded and sham-controlled across 160 participants, aimed at a De Novo request - the FDA route for a device with no marketed equivalent.
Risks Investors Should Watch
The listing question dominates. A Hearings Panel can grant an extension, but it can also uphold the delisting, pushing the stock to over-the-counter trading and complicating future capital raising.
Management has stated it lacks sufficient cash to fund at least twelve months of operations, and substantial doubt about Going Concern is disclosed in the filing. Against a $3.5 million half-year burn, $1.0 million of cash plus $2.65 million of ATM headroom is a short runway, with pivotal-trial costs still to come. Dilution is therefore near-certain.
Revenue has collapsed year on year, no Nexalin device is FDA-cleared for its target indications, and the Brazilian data came from a small, single-centre, open-label study without a sham arm.
What Comes Next
The Nasdaq Hearings Panel decision is the immediate event, and the board will likely time any reverse split around the panel guidance.
Clinically, watch enrolment in the HALO Clarity insomnia trial, an amended Q-Submission for the Alzheimer's programme, and two abstracts accepted for the 2026 NYC Neuromodulation Conference. Nexalin has also said it is preparing a Brazilian product launch. Third-quarter results are due in November.
Conclusion
Nexalin's clinical data genuinely stands out, a 77.8% anxiety response rate is a strong signal for a non-invasive brain stimulation approach, and the FDA's acceptance of an Alzheimer's Q-Submission shows the platform has regulatory traction beyond a single indication. But none of that changes the immediate corporate reality: the company is actively appealing a Nasdaq delisting determination with just over $1 million in cash and revenue that's collapsed year over year. The Hearings Panel decision, not any clinical readout, is the event most likely to determine Nexalin's near-term trajectory, since a rejected appeal would push the stock to over-the-counter trading and further complicate the capital raising this company clearly still needs.






Please wait processing your request...